A pathologist’s perspective on induced pluripotent stem cells
journal contributionposted on 05.03.2019 by Naohiro Terada, Noriko Watanabe, Katherine E. Santostefano, Anthony T. Yachnis
Any type of content formally published in an academic journal, usually following a peer-review process.
Induced pluripotent stem cell (iPSC) technology was originally developed in 2006. Essentially, it converts somatic cells into pluripotent stem cells by transiently expressing a few transcriptional factors. Once generated, these iPSCs can differentiate into all the cell types of our body, theoretically, which has attracted great attention for clinical research including disease pathobiology studies. Could this technology then become an additional research or diagnostic tool widely available to practicing pathologists? Here we summarize progress in iPSC research toward disease pathobiology studies, its future potential, and remaining problems from a pathologist’s perspective. A particular focus will be on introducing the effort to recapitulate disease-related morphological changes through three-dimensional culture of stem cells such as organoid differentiation.